Ross Camidge
Professor of Medicine and Director of the Thoracic Oncology Clinical and Clinical Research Programs. · University of Colorado School of Medicine
Credentials: · · ·
History
- Present
Medicine and Director of the Thoracic Oncology Clinical and Clinical Research Programs. · University of Colorado School of Medicine
- 1998–2000
Medical Oncology
- 1991–1995
OXFORD UNIV, OXFORD
- 1994–1995
- 1987–1991
Research
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
New England Journal of Medicine · 2010 · 3,649 citations
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
New England Journal of Medicine · 2013 · 2,828 citations
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2017 · 2,039 citations
- RD
56 papers
34 papers
33 papers · 12 as a resident
31 papers
26 papers
24 papers
- GR
21 papers
- SO
21 papers
Grants
- 2008–2012
A Randomized Phase II Study of Erlotinib with or Without the Anti-IGF-1R Monoclon
National Cancer Institute · R21
Contact PI · $717.4K · University of Colorado Denver
Clinical trials
- 2022–2023
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Principal investigator · Terminated · Phase 1, Phase 2
Criterium, Inc.
- 2016–2020
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
Principal investigator · Completed · Phase 1, Phase 2
Symphogen A/S
- 2014–2016
Principal investigator · Terminated · Phase 2
SWOG Cancer Research Network
- 2008–2012
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)